

Remarks

Applicants respectfully request entry of the foregoing specification amendment and revised claim set into the application. The specification and claims have been amended to add the ATCC accession number for the hybridoma cell line LL-2, which produces the LL2 antibody. The addition of the ATCC accession number does not introduce new matter. Claims 43 and 108 are currently being amended. Claims 39-43, 45-50, 52, 53, 75, 76, 107-111 remain in the case.

Applicants have also included with this filing a Statement of Availability, and attached a copy of the ATCC depository receipt indicating that the Hybridoma Cell Line LL-2 (03-20-91) has been assigned accession number PTA-6735.


CONCLUSION

In view of the above amendments and remarkd, it is respectfully submitted that this application is in condition for allowance. Early notice to that effect is earnestly solicited. The Examiner is invited to telephone the undersigned at the number listed below if the Examiner believes such would be helpful in advancing the application to issue.

If any additional fees are required for the filing of this paper, applicants authorize the Commissioner to charge any deficiency to Deposit Account No. 08-1641.

Respectfully submitted,

Date: June 3, 2005

By  _____

Customer No. 26633
HELLER EHRMAN WHITE &
MCAULIFFE LLP
1666 K Street, N.W., Suite 300
Washington, DC 20006
Telephone: (202) 912-2000
Facsimile: (202) 912-2020

Paul M. Booth
Attorney for applicant
Registration No. 40,244



Attorney Docket No.: 40923-0080 US4
(Previous Docket No. 018733/0967)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:
Goldenberg *et al.*

Confirmation No.: 3453

Application No.: 09/590,284

Art Unit: 1644

Filed: June 9, 2000

Examiner: Ilia Ouspenski

For: **IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS USING ANTIBODIES
WHICH TARGET B-CELLS**

STATEMENT OF AVAILABILITY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I, David M. Goldenberg, am the Chairman & Chief Strategic Officer at Immunomedics, Inc.

1. I hereby declare that the hybridoma cell line LL-2 has been deposited by Immunomedics, Inc. with the American Type Culture Collection as a Budapest Treaty Patent Deposit. The deposit has been assigned accession number PTA-6735. A copy of the deposit receipt for the American Type Culture Collection is attached as Tab 1.

2. Immunomedics will irrevocably remove all restrictions on the availability of the deposit upon the granting of a patent.

I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements and the like are made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under


Attorney Docket No.: 40923-0080 US4
(Previous Docket No. 018733/0967)

Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.


Respectfully submitted,

Date: June 3, 2005

By



David M. Goldenberg



AMERICAN TYPE CULTURE COLLECTION

10801 University Blvd.
Manassas, VA 20110-2209
Telephone: 703-365-2700
Fax: 703-365-2745

FACSIMILE

Date: June 2, 2005

To: Timothy Qu
Fax Number: 973-605-1340

From: ATCC Patent Depository **Number of pages:** 1 (Including this page)

REFERENCE: Patent Deposit (Ref: Docket or Case No: 40923-0080 US4/US 09/590,284)

Description: Hybridoma Cell Line: LL-2(03-20-91) assigned PTA-6735.

Date of Deposit: May 27, 2005

The ATCC Certificate of Deposit will be forwarded to you within 30 days. An invoice will be sent under separate cover referencing PU# 52025 as follows:

Total Fees for PTA-6735 **\$ 2,500.00**
(Storage/informing/viability testing)

Marie Harris, Patent Specialist
ATCC Patent Depository

The information contained in this facsimile is intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are notified that any dissemination or distribution, except to the intended recipient of this communication, is prohibited. If you have received this communication in error, please call us immediately at the telephone number listed above.